UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 85.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 83,231 shares of the company's stock after selling 493,214 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.17% of Amphastar Pharmaceuticals worth $3,090,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its holdings in Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after buying an additional 348 shares in the last quarter. Huntington National Bank increased its position in shares of Amphastar Pharmaceuticals by 36.9% during the fourth quarter. Huntington National Bank now owns 1,340 shares of the company's stock worth $50,000 after acquiring an additional 361 shares during the period. Bank of Montreal Can increased its position in shares of Amphastar Pharmaceuticals by 4.6% during the fourth quarter. Bank of Montreal Can now owns 8,215 shares of the company's stock worth $305,000 after acquiring an additional 361 shares during the period. TD Private Client Wealth LLC raised its stake in shares of Amphastar Pharmaceuticals by 22.7% in the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock valued at $78,000 after acquiring an additional 388 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its holdings in Amphastar Pharmaceuticals by 222.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after purchasing an additional 493 shares during the period. Hedge funds and other institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Stock Up 2.4%

Shares of NASDAQ:AMPH traded up $0.63 on Monday, hitting $26.62. 514,479 shares of the company's stock were exchanged, compared to its average volume of 486,287. Amphastar Pharmaceuticals, Inc. has a 1-year low of $22.64 and a 1-year high of $53.96. The company has a market capitalization of $1.25 billion, a PE ratio of 8.87, a P/E/G ratio of 2.19 and a beta of 0.77. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The firm's 50-day moving average is $24.62 and its 200 day moving average is $31.28.

Analyst Ratings Changes

Several brokerages have weighed in on AMPH. Wells Fargo & Company cut their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Piper Sandler reduced their target price on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a report on Friday, March 21st. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $30.00 price target (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $32.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.